Burcon revenue rises 191% in second quarter as shipments falter and financing pressure mounts
Key Facts
Burcon NutraScience reported results on November 16 for the second quarter of its 2027 fiscal year, ended September 30, posting revenue of C$1,040,829, up approximately 191% from the same period a year earlier. The company attributed the revenue growth to higher protein sales as commercial production increased at its Galesburg facility. Chief Executive Kip Underwood said plant reliability and efficiency improvements, along with infrastructure challenges, constrained shipments during the quarter. He added that production volumes had “recovered and accelerated since the end of the quarter.” The results put sales growth at the forefront of the report, despite operational constraints that affected product deliveries during the period.
For the six months ended September 30, revenue totaled C$2,317,041, up approximately 231% year over year. But the net loss widened to C$7.9 million, or $0.62 per share, compared with a loss of $7.0 million, or $0.56 per share, in the same period of the prior year. These figures cover the first half of the fiscal year and do not represent the second quarter alone. Burcon reported fiscal first-quarter revenue of C$1.3 million, up 54% from the quarter ended in March and 273% from a year earlier, with a net loss of $3.8 million, or $0.30 per share. The first-half results provide a picture of revenue growth alongside continuing losses.
The company used C$4.4 million in cash for operating activities during the six months, compared with $4.7 million used in the same period a year earlier. As of September 30, its cash balance was C$1.0 million, while working capital showed a deficit of $15.0 million. Burcon said it was evaluating short- and long-term financing options, but noted that it could not guarantee it would obtain additional financing on acceptable terms. Cash available at the end of June was $0.9 million, with a working capital deficit of $11.2 million. The figures highlight financing needs alongside accelerating sales as the company continues to expand commercial production.
In a financing development announced on the day of the results, Burcon entered into a loan agreement of up to C$4.2 million with the James P Pekar Family Endowment Trust, which is associated with board member James Pekar. The loan carries an annual interest rate of 15% and is due on November 16, 2027. The agreement comes as the company says it is evaluating other sources of financing, with a cash balance of C$1.0 million and a working capital deficit at the end of September. The loan terms, including the interest rate and maturity date, underscore the significance of the financing in the context of the company’s commercial expansion plans. The information available here did not include details on how much of the loan facility had actually been drawn.
Burcon announced commercial guidance on September 24 targeting revenue of at least C$6 million during calendar year 2026. It also set a target of an annualized revenue run rate of at least C$10 million exiting the year, and said it was targeting positive cash flow in 2027. These goals are the company’s stated indicators for the period ahead, while the six-month results showed strong annual revenue growth and continuing losses. The company held an investor conference call and webcast on November 16 at 5:00 p.m. Eastern Time to discuss the results. BRCNF shares closed at $0.5937 on November 13, the latest closing price included in the data provided.